MariMed Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

NOTE 3 - EQUITY

NOTE 3 - EQUITY	12 Months Ended
Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
NOTE 3 – EQUITY	NOTE 3 - USE OF EQUITY AS COMPENSATION During the year ended December 31, 2016 the Company issued 31,954,237 shares of common stock related to the acquisition of all the outstanding equity of Sigal from its members by our wholly owned subsidiary, MariMed. The acquisition occurred in 2014 but the shares were delivered in April of 2016. During the year ended December 31, 2016 the Company issued 300,000 shares of preferred stock. The preferred stock accrues a dividend of six percent and converts along with the accrued dividend into common stock at a twenty five percent discount to the selling price of the common stock in a qualified round. During the year ended December 31, 2016, the Company issued 1,070,000 warrants to six accredited investors. The warrants allow the investors to purchase 1,070,000 shares of the Company's common stock at $0.10 per share per each warrant. The warrants expire between February and November of 2019. The Company issued an additional 60,000 warrants with the issuance of preferred stock to five accredited investors. The warrants allow the investors to purchase 60,000 shares of the Company's common stock at $0.50 per share per each warrant. The warrants expire in October of 2019. During the year ended December 31, 2016, two of the outstanding notes were converted into Mia Development Class A shares. During the year ended December 31, 2015, the Company issued an aggregate of 166,210 shares of common stock as payment for an accrued expense with an aggregate value of $22,375. During the year ended December 31, 2015, the Company issued 300,000 options to the Company's directors. The directors each received 100,000 options for serving as board members in 2015. The stock options allow each director to purchase 100,000 shares of the Company's common stock at $0.13 per share per each individual option. An additional 300,000 options were issued to the Chief Financial Officer of the Company. The stock options to the Company's Chief Financial Officer allow for the purchase of 300,000 shares of the Company's common stock at $0.13 per share per each individual option. The options expire on June 29, 2020. Refer to Note 6 for further discussion. During the year ended December 31, 2015, the Company issued 55,000 warrants to two accredited investors. The warrants allow the investors to purchase 55,000 shares of the Company's common stock at $0.10 per share per each warrant. The warrants expire on June 30, 2018.

NOTE 3 - EQUITY

12 Months Ended

Dec. 31, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

NOTE 3 - USE OF EQUITY AS COMPENSATION

During the year ended December 31, 2016 the Company issued 31,954,237 shares of common stock related to the acquisition of all the outstanding equity of Sigal from its members by our wholly owned subsidiary, MariMed. The acquisition occurred in 2014 but the shares were delivered in April of 2016.

During the year ended December 31, 2016 the Company issued 300,000 shares of preferred stock. The preferred stock accrues a dividend of six percent and converts along with the accrued dividend into common stock at a twenty five percent discount to the selling price of the common stock in a qualified round.

During the year ended December 31, 2016, the Company issued 1,070,000 warrants to six accredited investors. The warrants allow the investors to purchase 1,070,000 shares of the Company's common stock at $0.10 per share per each warrant. The warrants expire between February and November of 2019. The Company issued an additional 60,000 warrants with the issuance of preferred stock to five accredited investors. The warrants allow the investors to purchase 60,000 shares of the Company's common stock at $0.50 per share per each warrant. The warrants expire in October of 2019.

During the year ended December 31, 2016, two of the outstanding notes were converted into Mia Development Class A shares.

During the year ended December 31, 2015, the Company issued an aggregate of 166,210 shares of common stock as payment for an accrued expense with an aggregate value of $22,375.

During the year ended December 31, 2015, the Company issued 300,000 options to the Company's directors. The directors each received 100,000 options for serving as board members in 2015. The stock options allow each director to purchase 100,000 shares of the Company's common stock at $0.13 per share per each individual option. An additional 300,000 options were issued to the Chief Financial Officer of the Company. The stock options to the Company's Chief Financial Officer allow for the purchase of 300,000 shares of the Company's common stock at $0.13 per share per each individual option. The options expire on June 29, 2020. Refer to Note 6 for further discussion.

During the year ended December 31, 2015, the Company issued 55,000 warrants to two accredited investors. The warrants allow the investors to purchase 55,000 shares of the Company's common stock at $0.10 per share per each warrant. The warrants expire on June 30, 2018.